Literature DB >> 12653886

Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1.

Peter A Gochee1, Julie R Jonsson, Andrew D Clouston, Nirmala Pandeya, David M Purdie, Elizabeth E Powell.   

Abstract

BACKGROUND: Increased levels of tumor necrosis factor (TNF)-alpha and oxidative stress have been implicated as factors contributing to hepatic injury in fatty liver diseases. As steatosis is associated with an accelerated progression of fibrosis in chronic hepatitis C (HCV), we hypothesized that the messenger (m)RNA expression of genes involved with the production of reactive oxygen species, inflammation and cellular injury would be increased in liver tissue from subjects with steatosis and chronic HCV.
METHODS: Real-time polymerase chain reaction was performed to determine relative mRNA expression levels of collagen I, TNF-alpha, cytochrome P450 2E1 (CYP 2E1), transforming growth factor-beta1 and CD14 in liver biopsies from 38 patients with chronic HCV. The mRNA expression levels were compared between subjects with and without steatosis, fibrosis, and inflammation.
RESULTS: Multivariate analysis demonstrated that collagen I mRNA expression was increased by 199% in steatosis (P = 0.02), 85% in moderate to severe fibrosis (P = 0.02) and 157% in inflammation (P = 0.03). Livers of patients with steatosis also had an increase in TNF-alpha mRNA expression by 50% (P = 0.03) and CYP 2E1 expression by 37% (P = 0.04) compared with non-steatotic livers. Tumor necrosis factor-alpha protein was localized to Kupffer cells, bile ducts and portal inflammatory cells by immunohistochemistry.
CONCLUSION: Increased expression of TNF-alpha may be involved in the pathogenesis of liver injury and progression of fibrosis in individuals who have steatosis in association with chronic HCV. Copyright 2003 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653886     DOI: 10.1046/j.1440-1746.2003.02984.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  22 in total

Review 1.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Hepatitis C virus infection and nonalcoholic steatohepatitis.

Authors:  Anish Patel; Stephen A Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-05

3.  Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease.

Authors:  Anatol Panasiuk; Janusz Dzieciol; Bozena Panasiuk; Danuta Prokopowicz
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

4.  Changes in lipid metabolism in chronic hepatitis C.

Authors:  Katalin Jármay; Gizella Karácsony; András Nagy; Zsuzsa Schaff
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

5.  Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees.

Authors:  Catherine B Bigger; Bernadette Guerra; Kathleen M Brasky; Gene Hubbard; Michael R Beard; Bruce A Luxon; Stanley M Lemon; Robert E Lanford
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 6.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

7.  Role of free radicals in liver diseases.

Authors:  Pablo Muriel
Journal:  Hepatol Int       Date:  2009-11-26       Impact factor: 6.047

8.  Efficacy of MK615 for the treatment of patients with liver disorders.

Authors:  Atsushi Hokari; Tomohisa Ishikawa; Hisao Tajiri; Takahide Matsuda; Osamu Ishii; Nobuyuki Matsumoto; Chiaki Okuse; Hideaki Takahashi; Takeshi Kurihara; Ko-Ichi Kawahara; Ikuro Maruyama; Mikio Zeniya
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

Review 9.  Underlying pathophysiology of HCV infection in HIV-positive drug users.

Authors:  Anuradha Balasubramanian; Jerome E Groopman; Ramesh K Ganju
Journal:  J Addict Dis       Date:  2008

10.  Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C.

Authors:  Hidenao Noritake; Yoshimasa Kobayashi; Yukimasa Ooba; Erika Matsunaga; Kazuyoshi Ohta; Shin Shimoyama; Satoru Yamazaki; Takeshi Chida; Kazuhito Kawata; Takanori Sakaguchi; Takafumi Suda
Journal:  J Interferon Cytokine Res       Date:  2015-08-26       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.